# US 12,702,786 B1 · Modulating sensory perceptions during psychedelic induced therapy > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 12,702,786 B1 - Document ID: US12702786B1 - Status: Granted - Kind: B1 - Application number: 17/875,506 - Filed: 2022-07-28 - Granted: 2026-08-11 - Earliest claimed: 2021-07-28 - Assignees: Medda, Inc. - Applicants: Medda, Inc. - Inventors: Caleb McClain; Jeffrey Humpherys; Mounir Bendahmane - Web page: https://patentgrep.com/patent/US12702786B1 ## CPC - A61M 21/00: Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis - A61M 21/0094: {Isolation chambers used therewith, i.e. for isolating individuals from external stimuli (other treatment rooms or enclosures A61G10/00)} - A61M 2021/0016: {by the smell sense} - A61M 2021/0022: {by the tactile sense, e.g. vibrations} - A61M 2021/0027: {by the hearing sense} - A61M 2021/0044: {by the sight sense} - A61M 2021/005: {images, e.g. video} - A61M 2202/0007: introduced into the body - A61M 2205/05: combined with other kinds of therapy - A61M 2205/3375: Acoustical, e.g. ultrasonic, measuring means - A61M 2205/507: Head Mounted Displays [HMD] - A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)} ## Abstract The present invention extends to methods, systems, and computer program products for modulating sensory perceptions during psychedelic induced therapy. Remote distributed virtual environments can be created enabling virtual group psychedelic therapy. Visual, auditory, and olfactory devices can be used to alter a patients' baseline sensory perceptions and obfuscate or limit knowledge about whether a patient was in the treatment or control group within placebo-controlled clinical trials. Various mechanisms are used to administer psychedelic drugs to a patient and accumulate psychedelic drugs in specific areas of the brain. Virtual environments can be tailored and specific brain wave states induced enabling targeted therapeutic outcomes in psychedelic therapy. ## Claims ### Claim 1 A method comprising: administrating a psychoactive agent to a patient; receiving virtual environment code from a cluster; executing the virtual environment code while the patient is under the influence of the psychoactive agent, including: simulating a patient virtual environment including visual stimuli, auditory stimuli, and olfactory stimuli; presenting the patient virtual environment to the patient, including the visual stimuli, auditory stimuli, and olfactory stimuli, using one or more hardware devices; modulating the visual stimuli, the auditory stimuli, and the olfactory stimuli within the patient virtual environment to induce a specific patient response; and presenting the patient virtual environment to the patient again, including the modulated visual stimuli, modulated auditory stimuli, and modulated olfactory stimuli, using the one or more hardware devices. ### Claim 2 (depends on 1) The method of claim 1, further comprising utilizing sensory deprivation of the patient prior to executing the virtual environment code. ### Claim 3 (depends on 1) The method of claim 1, further comprising emitting isochronic or binaural tones through an audio device, included in the one or more hardware devices and worn by the patient. ### Claim 4 (depends on 1) The method of claim 1, wherein modulating the visual stimuli, auditory stimuli, and olfactory stimuli within the patient virtual environment comprises emitting a sound through an audio device. ### Claim 5 (depends on 1) The method of claim 1, wherein modulating the visual stimuli, auditory stimuli, and olfactory stimuli within the patient virtual environment comprises emitting a scent at aromatics equipment. ### Claim 6 (depends on 1) The method of claim 1, wherein simulating the patient virtual environment comprises simulating a distributed virtual environment (DVE). ### Claim 7 (depends on 1) The method of claim 1, wherein executing the virtual environment code comprises including a 3D digital representation of an object associated with the patient in the patient virtual environment. ### Claim 8 (depends on 1) The method of claim 1, wherein administrating the psychoactive agent to the patient comprises administering the psychoactive agent via one of: intranasal, inhalation, oral ingestion, or intravenously. ### Claim 9 (depends on 1) The method of claim 1, further comprising: injecting microbubbles into the patient; controlling focused ultrasound (FUS) equipment to move the microbubbles to accumulate the psychoactive agent in a targeted brain region of the patient. ### Claim 10 (depends on 1) The method of claim 1, wherein modulating the visual stimuli, the auditory stimuli, and the olfactory stimuli within the patient virtual environment to induce the specific patient response comprises modulating the visual stimuli, the auditory stimuli, and the olfactory stimuli within the patient virtual environment to induce a specific patient therapeutic outcome. ### Claim 11 (depends on 1) The method of claim 1, wherein modulating the visual stimuli, the auditory stimuli, and the olfactory stimuli within the patient virtual environment to induce the specific patient response comprises modulating the visual stimuli, the auditory stimuli, and the olfactory stimuli within the patient virtual environment to induce a specific patient psychophysical outcome. ### Claim 12 (depends on 1) The method of claim 1, wherein presenting the patient virtual environment to the patient, including the visual stimuli, auditory stimuli, and olfactory stimuli, using one or more hardware devices comprises presenting auditory cortex simulation introducing various audible tones and rhythms during a psychedelic, or simulated psychedelic, therapy session. ### Claim 13 (depends on 1) The method of claim 1, wherein presenting the patient virtual environment to the patient, including the visual stimuli, auditory stimuli, and olfactory stimuli, using one or more hardware devices comprises presenting a soundscape or specific sonic frequencies associated with one or more of: a specific brain wave state, a state of consciousness, or a psychophysical response, tailored to support a therapeutic outcome. ### Claim 14 (depends on 1) The method of claim 1, wherein presenting the patient virtual environment to the patient, including the visual stimuli, auditory stimuli, and olfactory stimuli, using one or more hardware devices comprises presenting the patient virtual environment to the patient obfuscating whether the patient is in a control arm of a clinical trial or in a drug arm of the clinical trial. ### Claim 15 A method comprising: administrating a psychoactive agent to a patient; receiving virtual environment code from a cluster; executing the virtual environment code while the patient is under the influence of the psychoactive agent, including: simulating a distributed virtual environment including visual stimuli, auditory stimuli, and olfactory stimuli for the patient and including visual stimuli, auditory stimuli, and olfactory stimuli for one or more other participants; presenting the distributed virtual environment to the patient, including the visual stimuli, auditory stimuli, and olfactory stimuli, using one or more hardware devices, wherein one or more of the visual stimuli, auditory stimuli, and olfactory stimuli are presented based on actions of the one or more other participants having previously been presented the visual stimuli, auditory stimuli, and olfactory stimuli using the one or more hardware devices; modulating the visual stimuli, the auditory stimuli, and the olfactory stimuli within the distributed virtual environment based at least in part on the actions of the one or more other participants; and presenting the distributed virtual environment to the patient, including the modulated visual stimuli, modulated auditory stimuli, and modulated olfactory stimuli, using the one or more hardware devices. ### Claim 16 (depends on 15) The method of claim 15, wherein at least one of the one or more other participants is a clinician supervising a psychedelic assisted therapy session of the patient. ### Claim 17 (depends on 15) The method of claim 15, wherein the one or more other participants are part of interactive group therapy during a psychedelic assisted therapy session.